May 26th, 2020 | 07:43 CEST
BioNTech, Evotec, XPhyto - will the next rally start?
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Cannabis expertise for German brewing
XPhyto Therapeutics is not yet as well known in Germany as the renowned partners and institutions with which the Canadian cannabis company cooperates in this country. The renowned and world-famous German brewery Oettinger has recently agreed to cooperate with XPhyto. As a common goal the cooperation in the field of development as well as production and distribution of new cannabis spiked beverages and products has been agreed. XPhyto's expertise is in the formulation and clinical validation of cannabis products in the growing European market.
Through a wholly owned subsidiary in Germany, the company has obtained a unique license for the cultivation and extraction of cannabis for research purposes from the German Federal Institute for Drugs and Medical Devices. In addition, XPhyto, through its subsidiary, has two R&D collaboration agreements with the Faculty of Chemistry and the Chair of Beverage and Brewing Technology at the Technical University of Munich. With a share price of CAD 3.25, the company is valued at CAD 176 million and is not far from its high of CAD 3.55.
Individual cancer therapies to cure
BioNTech's stock is also on the rise, and yesterday closed with a gain of EUR 1.53 or 3.3% at a price of EUR 48.40. The market value of the German biotech company already exceeds EUR 10 billion. At its annual high, the share was already trading at over EUR 60.00. BioNTech is focused on new and individual cancer therapies and is currently working with renowned partners on the development of a vaccine for Covid-19. In connection with the Corona Pandemic and possible test results, the company is expected to remain in the focus of reporting in the coming months.
Product research and development
The biotech company Evotec is currently valued at EUR 3.6 billion. The shares changed hands at EUR 24.03. At its all-time high, Evotec was traded at over EUR 27.00. As a drug discovery and development company, Evotec drives new solutions and pharmaceutical products with partners and alliances. The company's experts operate worldwide and, according to the company's own statements, have state-of-the-art technologies and proven expertise in the core therapeutic areas of neuroscience, diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.